Literature DB >> 27619650

CRISPR as a driving force: the Model T of biotechnology.

Carlos Mariscal1, Angel Petropanagos2.   

Abstract

The CRISPR system for gene editing can break, repair, and replace targeted sections of DNA. Although CRISPR gene editing has important therapeutic potential, it raises several ethical concerns. Some bioethicists worry CRISPR is a prelude to a dystopian future, while others maintain it should not be feared because it is analogous to past biotechnologies. In the scientific literature, CRISPR is often discussed as a revolutionary technology. In this paper we unpack the framing of CRISPR as a revolutionary technology and contrast it with framing it as a value-threatening biotechnology or business-as-usual. By drawing on a comparison between CRISPR and the Ford Model T, we argue CRISPR is revolutionary as a product, process, and as a force for social change. This characterization of CRISPR offers important conceptual clarity to the existing debates surrounding CRISPR. In particular, conceptualizing CRISPR as a revolutionary technology structures regulatory goals with respect to this new technology. Revolutionary technologies have characteristic patterns of implementation, entrenchment, and social impact. As such, early identification of technologies as revolutionary may help construct more nuanced and effective ethical frameworks for public policy.

Keywords:  Biotechnology; CRISPR; CRISPR/Cas9; Gene editing; Gene therapy; Revolutionary technology

Mesh:

Substances:

Year:  2016        PMID: 27619650     DOI: 10.1007/s40592-016-0062-2

Source DB:  PubMed          Journal:  Monash Bioeth Rev        ISSN: 1321-2753


  45 in total

1.  Leukaemia success heralds wave of gene-editing therapies.

Authors:  Sara Reardon
Journal:  Nature       Date:  2015-11-12       Impact factor: 49.962

2.  Removing allergens and reducing toxins from food crops.

Authors:  Maria Gallo; Richard Sayre
Journal:  Curr Opin Biotechnol       Date:  2009-04-06       Impact factor: 9.740

3.  Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems.

Authors:  Wei Li; Fei Teng; Tianda Li; Qi Zhou
Journal:  Nat Biotechnol       Date:  2013-08       Impact factor: 54.908

4.  Gene-edited CRISPR mushroom escapes US regulation.

Authors:  Emily Waltz
Journal:  Nature       Date:  2016-04-21       Impact factor: 49.962

5.  Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome.

Authors:  Daniel G Gibson; Gwynedd A Benders; Cynthia Andrews-Pfannkoch; Evgeniya A Denisova; Holly Baden-Tillson; Jayshree Zaveri; Timothy B Stockwell; Anushka Brownley; David W Thomas; Mikkel A Algire; Chuck Merryman; Lei Young; Vladimir N Noskov; John I Glass; J Craig Venter; Clyde A Hutchison; Hamilton O Smith
Journal:  Science       Date:  2008-01-24       Impact factor: 47.728

6.  Gene therapy for human genetic disease?

Authors:  T Friedmann; R Roblin
Journal:  Science       Date:  1972-03-03       Impact factor: 47.728

7.  Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs.

Authors:  Qiurong Ding; Stephanie N Regan; Yulei Xia; Leoníe A Oostrom; Chad A Cowan; Kiran Musunuru
Journal:  Cell Stem Cell       Date:  2013-04-04       Impact factor: 24.633

8.  RNA-programmed genome editing in human cells.

Authors:  Martin Jinek; Alexandra East; Aaron Cheng; Steven Lin; Enbo Ma; Jennifer Doudna
Journal:  Elife       Date:  2013-01-29       Impact factor: 8.140

9.  RNA-guided editing of bacterial genomes using CRISPR-Cas systems.

Authors:  Wenyan Jiang; David Bikard; David Cox; Feng Zhang; Luciano A Marraffini
Journal:  Nat Biotechnol       Date:  2013-01-29       Impact factor: 54.908

Review 10.  Concerning RNA-guided gene drives for the alteration of wild populations.

Authors:  Kevin M Esvelt; Andrea L Smidler; Flaminia Catteruccia; George M Church
Journal:  Elife       Date:  2014-07-17       Impact factor: 8.140

View more
  1 in total

Review 1.  Public Attitudes toward Gene Therapy in China.

Authors:  Jiang-Hui Wang; Rong Wang; Jia Hui Lee; Tiara W U Iao; Xiao Hu; Yu-Meng Wang; Lei-Lei Tu; Yi Mou; Wen-Li Zhu; Ai-Yong He; Shen-Yu Zhu; Di Cao; Lei Yang; Xiao-Bo Tan; Qing Zhang; Guan-Lu Liang; Shu-Min Tang; Ye-Di Zhou; Li-Jun Feng; Li-Jun Zhan; Nan-Nan Tian; Ming-Jie Tang; Ya-Ping Yang; Moeen Riaz; Peter van Wijngaarden; Gregory J Dusting; Guei-Sheung Liu; Yan He
Journal:  Mol Ther Methods Clin Dev       Date:  2017-06-20       Impact factor: 6.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.